Hemodynamic parameters were compared using non-parametric Kruskal-Wallis tests ... 61.8% (range 50.9–69.0%), and 83.1% (range 71.4–90.2%), respectively. Wilcoxon rank sum test demonstrated differences ...

Objective Patients with increased PD-L1 + host cells in tumours are more potent to benefit from antiprogrammed death-1/programmed death ligand-1 (PD-L1) treatment, but the underlying mechanism is ...

Past performance is not indicative of future results. The above frequency distribution chart presents information about the difference between the daily market price for shares of the Fund and the ...